• +1-646-491-9876
    • +91-20-67278686

    Search

    Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha-Pipeline Review H2 2017

    Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha-Pipeline Review H2 2017

    • Report Code ID: RW0001881476
    • Category Life Sciences
    • No. of Pages 68
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)-Pipeline Review H2 2017

    Summary

    According to the recently published report 'Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha-Pipeline Review H2 2017'; Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.

    Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)-Granulocyte macrophage colony stimulating factor receptor subunit alpha also known as CD116 is a receptor for granulocyte macrophage colony-stimulating factor. It is a member of the cytokine family of receptors. It plays an important role in controls the production differentiation and function of granulocytes and macrophages.

    The report 'Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha-Pipeline Review H2 2017' outlays comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics complete with analysis by indications stage of development mechanism of action (MoA) route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

    It also reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics development with respective active and dormant or discontinued projects. Currently The molecules developed by companies in Phase III Phase II Phase I and Preclinical stages are 2 4 1 and 3 respectively. Similarly the universities portfolio in Preclinical stages comprises 1 molecules respectively. Report covers products from therapy areas Oncology Respiratory Toxicology Central Nervous System Dermatology Gastrointestinal and Infectious Disease which include indications Prostate Cancer Colorectal Cancer Lung Disease Melanoma Radiation Toxicity (Radiation Sickness Acute Radiation Syndrome) Acute Respiratory Distress Syndrome Alzheimer's Disease Appendicitis Asthma Chemotherapy Induced Neutropenia Chronic Obstructive Pulmonary Disease (COPD) Crohn's Disease (Regional Enteritis) Lung Infections Lung Injury Malignant Pleural Mesothelioma Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Mild Cognitive Impairment Neurology Ovarian Cancer Parkinson's Disease Peritonitis Radiation Induced Myelosuppression Radiation Injury Respiratory Syncytial Virus (RSV) Infections Skin Ulcers and Wounds.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)
    - The report reviews Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes product description descriptive MoA R&D brief licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics based on mechanism of action (MoA) route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information analysis and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)-Overview
    Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)-Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)-Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)-Companies Involved in Therapeutics Development
    Aduro BioTech Inc
    Bolder Biotechnology Inc
    Genzyme Corp
    Johnson & Johnson
    OncBioMune Pharmaceuticals Inc
    Pharmaxis Ltd
    Savara Inc
    Targovax ASA
    XL-protein GmbH
    Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)-Drug Profiles
    BBT-007-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GVAX Colorectal Cancer Vaccine-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    molgramostim-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    molgramostim-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    molgramostim-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ONCOS-102-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Prostatac-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PXS-2200-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein for RSV Infections-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sargramostim-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine for Prostate Cancer-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    XL-150-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)-Dormant Products
    Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)-Discontinued Products
    Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)-Product Development Milestones
    Featured News & Press Releases
    Jun 27 2017 Enrollment to Begin in OncBioMunes Trial of ProscaVax for Prostate Cancer in Mexico
    Jun 21 2017 OncBioMune Receives Patent Protecting Novel Cancer Vaccine in Mexico
    Jun 20 2017 OncBioMune Awarded Patent for ProscaVax in Japan
    Jun 07 2017 OncBioMune Protects ProscaVax Cancer Treatment Technology in Hong Kong
    Jun 01 2017 Protocol Submitted to FDA for Phase 2 Clinical Trial of ProscaVax as Immunotherapy for Early-Stage Prostate Cancer
    May 10 2017 Targovax recruits first patient into first ONCOS-102 /Checkpoint inhibitor melanoma study
    May 10 2017 Savara Announces Expedited U.S. Molgradex Development Strategy
    May 03 2017 OncBioMune Completes Enrollment in Phase 1 Trial of ProscaVax for Prostate Cancer
    Feb 02 2017 OncBioMune Announces Presentation on ProscaVax at the 2017 American Association for Cancer Research Meeting
    Jan 26 2017 Latest Clinical Data from OncBioMune Supports Safety and Therapeutic Profile of ProscaVax for Prostate Cancer for Upcoming Phase 2 Clinical Trials
    Jan 18 2017 Departments of Urology and Oncology Approve Protocol for OncBioMune's Phase 2/3 Trial of ProscaVax for Prostate Cancer in Mexico
    Jan 10 2017 OncBioMune Submitting Clinical Trial of World's First Early-Stage Prostate Cancer Vaccine to The Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute
    Dec 28 2016 Patients Pre-Screened for OncBioMune Pharmaceuticals Phase 2/3 Trial of ProscaVax for Prostate Cancer
    Dec 12 2016 OncBioMune Awarded Patent in Europe Protecting Novel Cancer Vaccine Technology
    Dec 08 2016 OncBioMune and the Clinical Trial Investigators Have Agreed Upon the Protocol for Their Phase 2 Trial of Novel Vaccine for Early Stage Prostate Cancer
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development H2 2017
    Number of Products under Development by Therapy Areas H2 2017
    Number of Products under Development by Indications H2 2017
    Number of Products under Development by Indications H2 2017 (Contd..1) H2 2017
    Number of Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017 (Contd..1) H2 2017
    Number of Products under Investigation by Universities/Institutes H2 2017
    Products under Investigation by Universities/Institutes H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Pipeline by Aduro BioTech Inc H2 2017
    Pipeline by Bolder Biotechnology Inc H2 2017
    Pipeline by Genzyme Corp H2 2017
    Pipeline by Johnson & Johnson H2 2017
    Pipeline by OncBioMune Pharmaceuticals Inc H2 2017
    Pipeline by Pharmaxis Ltd H2 2017
    Pipeline by Savara Inc H2 2017
    Pipeline by Targovax ASA H2 2017
    Pipeline by XL-protein GmbH H2 2017
    Dormant Products H2 2017
    Dormant Products H2 2017 (Contd..1) H2 2017
    Discontinued Products H2 2017

    List of Figures

    Number of Products under Development by Stage of Development H2 2017
    Number of Products under Development by Therapy Areas H2 2017
    Number of Products under Development by Top 10 Indications H2 2017
    Number of Products by Mechanism of Actions H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Top 10 Routes of Administration H2 2017
    Number of Products by Stage and Top 10 Routes of Administration H2 2017
    Number of Products by Molecule Types H2 2017
    Number of Products by Stage and Molecule Types H2 2017
    Aduro BioTech Inc
    Bolder Biotechnology Inc
    Genzyme Corp
    Johnson & Johnson
    OncBioMune Pharmaceuticals Inc
    Pharmaxis Ltd
    Savara Inc
    Targovax ASA
    XL-protein GmbH

    Request for Sample

    Report Url http://www.reportsweb.com//granulocyte-macrophage-colony-stimulating-factor-receptor-subunit-alpha-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//granulocyte-macrophage-colony-stimulating-factor-receptor-subunit-alpha-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//granulocyte-macrophage-colony-stimulating-factor-receptor-subunit-alpha-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments